Skip to content
Screener

MoonLake Immunotherapeutics MLTX Q2 2025 earnings

Reported August 5, 2025 · Before market open

EPS-$0.87Miss by $0.14
EPS estimate-$0.73

Next report

Aug 11, 2026 (In 2 days)
EPS estimate-$0.92

Financials

Q2 2025

Income statement

See full
Operating income-$60.7M-98.5%
Net income-$55.2M-128%
EPS (diluted)-$0.87-123%

Balance sheet

See full
Cash & equivalents$306.7M-10.5%
Total debt$75.8M+2,166%
Total equity$353.7M-32.1%
Total assets$460.1M-15.6%

Cash flow

See full
Operating cash flow-$54.5M-95.5%
Free cash flow-$54.5M-95.5%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$2.9B+5.5%
Enterprise value$2.67B+10.7%

Returns & leverage

See full
Return on equity-40.3%-63.8pp
Debt / equity0.2×+0.2×
Current ratio16.6×-27.1×

FAQ

When did MoonLake Immunotherapeutics report Q2 2025 earnings?
MoonLake Immunotherapeutics (MLTX) reported Q2 2025 earnings on August 5, 2025 before market open.
What were MoonLake Immunotherapeutics's Q2 2025 revenue and EPS?
MoonLake Immunotherapeutics reported eps of $-0.87 for Q2 2025.
Did MoonLake Immunotherapeutics beat estimates in Q2 2025?
EPS missed the consensus estimate of $-0.73 by $0.14.
How did MoonLake Immunotherapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 123.1% from $-0.39.
Where can I find MoonLake Immunotherapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001821586-25-000016) and the 10-Q periodic report (0001821586-25-000018) directly on SEC EDGAR. The filing index links above go to sec.gov.